Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Recent changes in the therapeutic strategy for NSCLC in association with new anti-cancer agents].

Rinsho byori. The Japanese journal of clinical pathology - 1 Apr 2013

Yatabe Yasushi

Abstract excerpt

Patients with SCLC (Small cell lung cancer) have been treated differently from those with NSCLC (New-small cell lung cancer) as a different disease. Recently, even patients with NSCLC are treated differently according to histological subtypes. This change is associated with the development of new drugs, particularly molecular-targeted drugs. Because Bevacizumab can cause serious adverse effects, patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to ALK gene

Share to Lung Neoplasms

Share to Mutation

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 23855189

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Recent changes in the therapeutic strategy for NSCLC in association with new anti-cancer agents].PMID 23855189Read ↗

[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].Semantic proximity Read ↗

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].Semantic proximity Read ↗

[Advances of molecular subtype and targeted therapy of lung cancer].Semantic proximity Read ↗

[Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].Semantic proximity Read ↗

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.Semantic proximity Read ↗

[New targets and new drugs in thoracic oncology].Semantic proximity Read ↗

[Molecular pathology of pulmonary carcinomas].Semantic proximity Read ↗

[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].Semantic proximity Read ↗

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].Semantic proximity Read ↗

[Treatment of Advanced Squamous Cell Lung Cancer].Semantic proximity Read ↗

[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].Semantic proximity Read ↗

[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.